Clinical trials
Phase 3 trials in the United Arab Emirates
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
73 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 6 |
| 2025 | 6 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 36 |
| Active, not recruiting | 13 |
| Recruiting | 12 |
| Unknown status | 6 |
| Terminated | 3 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 9 |
| Novo Nordisk A/S | 6 |
| Sanofi | 5 |
| AstraZeneca | 4 |
| Novartis Pharmaceuticals | 4 |
| AbbVie | 2 |
| Agios Pharmaceuticals, Inc. | 2 |
| Alnylam Pharmaceuticals | 2 |
| China National Biotec Group Company Limited | 2 |
| Eli Lilly and Company | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 10 |
| Breast Neoplasms | 9 |
| Diabetes Mellitus | 7 |
| COVID-19 | 5 |
| Acute Coronary Syndrome | 3 |
| Coronavirus Infections | 3 |
| Glucose Metabolism Disorders | 2 |
| Heart Failure | 2 |
| Hyperoxaluria, Primary | 2 |
| Hypertension | 2 |
Trials
Showing 51 to 73 of 73. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.